Journal
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
Volume 3, Issue 2, Pages 149-158Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/17425255.3.2.149
Keywords
chiral; cytochrome P450; drug interaction; drug metabolism; enantiomer; enantiomeric recognition; enantioselective; first-pass effect; induction; inhibition; racemate; species difference; stereoselectivity
Ask authors/readers for more resources
Many chiral drugs are used as their racemic mixtures in clinical practice. Two enantiomers of a chiral drug generally differ in pharmacodynamic and/or pharmacokinetic properties as a consequence of the stereoselective interaction with optically active biological macromolecules. Thus, a stereospecific assay to discriminate between enantiomers is required in order to relate plasma concentrations to pharmacological effect of a chiral drug. Stereo-selective metabolism of drugs is most commonly the major contributing factor to stereoselectivity in pharmacokinetics. Metabolizing enzymes often display a preference for one enantiomer of a chiral drug over the other, resulting in enantioselectivity. The structural characteristics of enzymes dictate the enantiomeric discrimination associated with the metabolism of chiral drugs. The stereoselectivity can, therefore, be viewed as the physical property characteristic that phenotypes the enzyme. This review provides a comprehensive appraisal of stereochemical aspects of drug metabolism (i.e., enantioselective metabolism and first-pass effect, enzyme-selective inhibition or induction and drug interaction, species differences and polymorphic metabolism).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available